Impax Laboratories, Inc. (NASDAQ:IPXL)‘s stock had its “market perform” rating reaffirmed by research analysts at BMO Capital Markets in a report released on Friday.

Several other analysts also recently weighed in on IPXL. RBC Capital Markets reaffirmed a “hold” rating and issued a $15.00 target price on shares of Impax Laboratories in a report on Tuesday, January 3rd. Deutsche Bank AG reaffirmed a “hold” rating and issued a $17.00 target price on shares of Impax Laboratories in a report on Friday, December 23rd. Janney Montgomery Scott began coverage on shares of Impax Laboratories in a report on Wednesday, December 28th. They issued a “neutral” rating and a $15.00 target price on the stock. Bank of America Corporation downgraded shares of Impax Laboratories from a “neutral” rating to an “underperform” rating and set a $19.00 target price on the stock. in a report on Monday, November 7th. Finally, WallachBeth Capital downgraded shares of Impax Laboratories from a “buy” rating to a “hold” rating and lowered their target price for the company from $30.00 to $18.00 in a report on Monday, November 14th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $27.13.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories (NASDAQ:IPXL) traded up 8.039% during mid-day trading on Friday, hitting $13.775. 571,205 shares of the stock traded hands. The company’s market cap is $982.57 million. The firm’s 50-day moving average is $13.66 and its 200-day moving average is $22.20. Impax Laboratories has a 12-month low of $11.88 and a 12-month high of $40.74.

Impax Laboratories (NASDAQ:IPXL) last issued its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $0.37 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.39 by $0.02. The firm earned $228 million during the quarter, compared to analysts’ expectations of $234.87 million. Impax Laboratories had a negative net margin of 19.93% and a positive return on equity of 11.34%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.40 EPS. Equities research analysts expect that Impax Laboratories will post $1.16 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Impax Laboratories’ (IPXL) “Market Perform” Rating Reaffirmed at BMO Capital Markets” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright and trademark law. The legal version of this news story can be viewed at http://www.dailypolitical.com/2017/01/13/impax-laboratories-ipxl-market-perform-rating-reaffirmed-at-bmo-capital-markets.html.

Institutional investors have recently made changes to their positions in the company. Seven Bridges Advisors LLC boosted its position in shares of Impax Laboratories by 0.3% in the second quarter. Seven Bridges Advisors LLC now owns 32,190 shares of the specialty pharmaceutical company’s stock worth $928,000 after buying an additional 108 shares during the last quarter. Boston Advisors LLC boosted its position in shares of Impax Laboratories by 1.1% in the second quarter. Boston Advisors LLC now owns 11,785 shares of the specialty pharmaceutical company’s stock worth $340,000 after buying an additional 125 shares during the last quarter. Mackenzie Financial Corp boosted its position in shares of Impax Laboratories by 1.0% in the second quarter. Mackenzie Financial Corp now owns 20,587 shares of the specialty pharmaceutical company’s stock worth $593,000 after buying an additional 200 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Impax Laboratories by 1.7% in the third quarter. Municipal Employees Retirement System of Michigan now owns 15,400 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 260 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its position in shares of Impax Laboratories by 0.7% in the second quarter. Public Employees Retirement System of Ohio now owns 45,803 shares of the specialty pharmaceutical company’s stock worth $1,320,000 after buying an additional 323 shares during the last quarter. Institutional investors own 84.22% of the company’s stock.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

5 Day Chart for NASDAQ:IPXL

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.